InflaRx (IFRX) EBITDA Margin Growth (1y) (2024 - 2026)
Powered by 
Analysis
InflaRx (IFRX) EBITDA Margin Growth (1y) (2024 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 602.00 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -16,814.00 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -143.00 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 78.00 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1,135.00 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 7,666.00 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 2,002.00 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -2,881.00 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -1.23 Mn |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Mn | 1.49 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.49 Mn |
| Dec 31, 2025 | -1.25 Bn |
| Sep 30, 2025 | -2.74 Mn |
| Jun 30, 2025 | 20.94 Mn |
| Mar 31, 2025 | -143,311.00 |
| Dec 31, 2024 | 1.45 Bn |
| Sep 30, 2024 | 593,408.00 |